Bayer’s carefully orchestrated plan to resolve its long-running glyphosate litigation faces new obstacles, casting doubt on its intended timeline. The company, which postponed its annual financial presentation specifically to account for a massive proposed settlement, now confronts requests from U.S. plaintiff attorneys to delay court proceedings. This development threatens to prolong the legal uncertainty the Leverkusen-based group aimed to conclude.
A Crucial Hearing in the Balance
The immediate conflict centers on a $7.25 billion settlement proposal designed to resolve tens of thousands of lawsuits. Law firms representing approximately 20,000 claimants have filed a motion with a Missouri court seeking to postpone a hearing scheduled for March 4, 2026. This hearing was intended to secure preliminary approval for the settlement agreement.
The legal teams contend that the documentation, which was transmitted on February 17 and exceeds 600 pages, requires more thorough review. They are requesting a delay of at least 60 days, arguing the current timeframe is insufficient for proper analysis. Bayer has countered, maintaining that the settlement terms are fair, but the uncertainty is weighing on investor sentiment. The company’s shares have declined roughly 7% over the past month, and with a Relative Strength Index (RSI) reading of 19.6, the stock is now technically in deeply oversold territory.
Should investors sell immediately? Or is it worth buying Bayer?
Pharmaceutical Division Sees Regulatory Progress
Amid the legal tensions, Bayer’s pharmaceuticals unit has reported a positive operational development. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted an additional approval for the 8-milligram dosage of the eye medication Eylea. The treatment is now also cleared for use in treating macular edema following retinal vein occlusion. This marks the drug’s third approved indication in the United Kingdom, bolstering the position of this key revenue driver. The authorization is based on positive data from the Phase III QUASAR study.
Strategic Communications at Risk
The coming days are critical for the company’s strategic messaging. Bayer’s management deliberately rescheduled the presentation of its 2025 annual results and outlook to Wednesday, March 4, 2026. This move was intended to allow the financial implications of the settlement to be reflected directly in its communications. Should the court grant the motion for a delay, the company may be forced to outline its guidance for the current business year without the hoped-for legal clarity, potentially undermining its planned narrative.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from February 28 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 28.
Bayer: Buy or sell? Read more here...
